Dr. Barbacid’s Study ‘Eliminates’ Pancreatic Cancer: Breakthrough Details

A Spanish researcher, Dr. Mariano Barbacid, has recently gained attention – particularly on the social media platform X (formerly Twitter) – for a medical advancement hailed by some as a potential breakthrough in cancer treatment. Dr. Barbacid, a senior scientist at the Spanish National Cancer Research Centre (CNIO), has reported promising results in the fight against pancreatic cancer, a disease often considered one of the most challenging to treat.

A Difficult Cancer, A New Approach

Adenocarcinoma ductal pancreatic cancer is often described as a “death sentence” in the medical community. It’s notoriously difficult to detect early, spreads rapidly, and demonstrates a remarkable ability to evade treatment. The majority of these cases are linked to a damaged gene called KRAS. While drugs like daraxonrasib aim to inhibit KRAS, the cancer frequently finds ways to survive.

According to researchers, “Cancer is smart. When one pathway is blocked, the tumor often finds ‘rat tunnels’ or alternative routes to continue growing,” as reported in their findings published in the journal PNAS.

Tripling Down on Treatment

Dr. Barbacid’s team pursued a different strategy: attacking the cancer from three angles simultaneously. The first drug, daraxonrasib, blocks the primary KRAS signal driving tumor growth. The second, afatinib, disables EGFR and HER2, pathways cancer cells often exploit to circumvent KRAS-targeting treatments. The third, SD36, deactivates STAT3, a backup system that helps cancer cells withstand stress and resist therapy.

When these three drugs were used in combination on mice, the pancreatic tumors completely shrank and did not reappear, even more than 200 days after treatment ceased. Similar effects were observed in genetically engineered mouse models and in tumors taken from human patients and grown in the laboratory.

Did You Know? The research team’s findings were published in the peer-reviewed journal PNAS, indicating a rigorous scientific review process.

What’s Next?

The treatment was well-tolerated by the animals, with no serious side effects observed, suggesting the combination may be safe for human trials. The core of the research demonstrates that pancreatic cancer may be overcome by simultaneously blocking its primary engine, its escape routes, and its emergency backup systems, leaving it with no means to adapt and fight back.

While currently limited to experimental models, researchers believe the results are strong enough to pave the way for new clinical trials. If successful in human patients, this approach could offer a new weapon against one of the world’s most deadly cancers.

Expert Insight: This multi-pronged approach represents a significant shift in cancer treatment strategy, moving beyond targeting a single pathway to disrupting the complex network of mechanisms that allow tumors to survive and evolve.

Frequently Asked Questions

What type of cancer did this research focus on?

The research focused specifically on adenocarcinoma ductal pancreatic cancer, a particularly aggressive and difficult-to-treat form of the disease.

What three drugs were used in the treatment?

The three drugs used were daraxonrasib, afatinib, and SD36.

How long after treatment ended were the tumors still absent?

The tumors did not reappear for more than 200 days after treatment was stopped.

Could this innovative approach to cancer treatment inspire further research into combination therapies for other types of cancer?